title: [Predictive value of diffusion-weighted imaging histogram in evaluation of the response to radiofrequency ablation in hepatocellular carcinoma].
abstract: OBJECTIVE
  To evaluate the value of MR diffusion-weighted imaging (DWI) histogram analysis for predicting tumor progression in patients with hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA).
  
  
  METHODS
  In a retrospective study, both 35 stable patients and 38 progressive patients with biopsy-proven HCC underwent breath-hold DWI before RFA treatment. The pre-treatment apparent diffusion coefficient (ADC) values were averaged from the lowest to 10th, 30th, 50th, and 100th percentile using DWI histogram analysis software respectively, and were called ADC10, ADC30, ADC50 and ADC100. The ratios of ADC10, ADC30, ADC50 and ADC100 to mean ADC of non-lesional area were calculated, called RADC10, RADC30, RADC50 and RADC100, respectively.
  
  
  RESULTS
  Before RFA treatment, the ADC30, ADC50, ADC100, RADC30, RADC50 and RADC100 values of the tumors in the progression group were significantly higher than those of the stable group (P < 0.05 for all), respectively. The progression-free survival (PFS) of all patients was (16.0 ± 10.6) months. Univariate Cox regression analysis indicated that RADC10, RADC30, RADC50 values of the tumor were significantly associated with PFS (P < 0.05 for both). In multivariate analysis, only the RADC50 value of tumor was a significant predictor for tumor progression (P < 0.05). When the cut-off value of RADC50 (0.72) was used, the PFS of below the cut-off value group [(30.2 ± 3.0) months] was significantly higher than that of those above the cut-off value group [(20.0 ± 3.1) months] (P = 0.01).
  
  
  CONCLUSIONS
  Pre-RFA DWI histogram analysis may serve as a biomarker for predicting tumor progression in patients with HCC treated with RFA.
authors.affiliation: Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Ma
authors.forename: Xinming
authors.initials: X
authors.lastname: Zhao
authors.forename: Han
authors.initials: H
authors.lastname: Ouyang
authors.forename: Shuang
authors.initials: S
authors.lastname: Wang
authors.forename: Feng
authors.initials: F
authors.lastname: Ye
authors.forename: Meng
authors.initials: M
authors.lastname: Wang
authors.affiliation: Email: cjr.zhouchunwu@vip.163.com.
authors.forename: Chunwu
authors.initials: C
authors.lastname: Zhou
mesh_terms: D000368:Aged; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D038524:Diffusion Magnetic Resonance Imaging; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008113:Liver Neoplasms; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies